This report provides a comprehensive analysis of the global quantum computing in drug discovery market, projecting significant growth through 2035. It examines key segments including hardware, software, and services, while detailing various quantum technologies and computational applications such as quantum simulation and machine learning. The study explores the entire drug discovery workflow, from target identification to preclinical selection, across diverse therapeutic areas. Additionally, the research evaluates competitive dynamics, regional trends, and deployment models to offer actionable intelligence for pharmaceutical and biopharmaceutical stakeholders.

Market Overview

Market Size and Growth

The Quantum Computing in Drug Discovery market reached US$ 126.11 million in 2025 and is projected to reach US$ 637.83 million by 2035, exhibiting a compound annual growth rate (CAGR) of 17.90% during the forecast period from 2026 to 2035.

Report Introduction

The Quantum Computing in Drug Discovery Market emerges as a key focus in DataM Intelligence's latest in-depth analysis. Seasoned researchers harness advanced data analytics and strategic foresight to deliver unparalleled market intelligence. This insightful report meticulously explores the competitive landscape, profiling key players and their forward-thinking innovations in product development, pricing strategies, financial metrics, and global expansion initiatives. By uncovering the driving forces, market dynamics, and disruptive trends shaping the future, this research equips industry stakeholders with the actionable insights needed to make informed decisions in an increasingly dynamic and competitive environment.

Definition and Functionality

A Quantum Computing in Drug Discovery Market is a data-driven software solution that collects, integrates, analyzes, and visualizes customer data across various touchpoints to generate actionable insights. These platforms help businesses understand customer behaviors, preferences, and purchasing patterns in real time, enabling personalized marketing, enhanced customer engagement, and data-driven decision-making.

Market Segmentation

By Offering

• Hardware
• Software
• Services

By Quantum Technology Type

• Superconducting Qubits
• Trapped-Ion Qubits
• Photonic Qubits
• Quantum Annealing
• Topological Qubits

By Drug Discovery Workflow Stage

• Target Identification & Validation
• Hit Generation/Lead Identification
• Lead Optimization
• Preclinical Candidate Selection

By Computational Application

• Quantum Simulation
• Quantum Optimization
• Quantum Machine Learning
• Quantum Sampling

By Deployment Model

• Cloud-Based
• On-Premises

By Therapeutic Area

• Oncology
• Infectious Diseases
• Cardiovascular Disorders
• Neurological Disorders
• Immunological Disorders
• Rare & Orphan Diseases
• Metabolic & Endocrine Disorders
• Others

By End-User

• Pharmaceutical Companies
• Biopharmaceutical Companies
• Contract Research Organizations (CROs)
• Academic & Research Institutes
• Others

Regional Analysis

• North America: U.S., Canada, Mexico
• Europe: U.K., Italy, Germany, Russia, France, Spain, The Netherlands, and Rest of Europe
• Asia-Pacific: India, Japan, China, South Korea, Australia, Indonesia, and Rest of Asia Pacific
• South America: Colombia, Brazil, Argentina, and Rest of South America
• Middle East & Africa: Saudi Arabia, U.A.E., South Africa, and Rest of Middle East & Africa

Scope of Report

This report encompasses the following analytical areas:

• Go-to-market Strategy.
• Neutral perspective on market performance.
• Development trends and competitive landscape analysis.
• Supply side analysis and demand side analysis.
• Year-on-year growth and competitive benchmarking.
• Vendor identification and other significant analysis, including development status.
• Customized regional/country reports as per request and country-level analysis.
• Potential and niche segments and regions exhibiting promising growth.
• Analysis of Market Size (historical and forecast), Total Addressable Market (TAM), Serviceable Available Market (SAM), Serviceable Obtainable Market (SOM), Market Growth, Technological Trends, Market Share, Market Dynamics, Competitive Landscape, and Major Players (Innovators, Start-ups, Laggards, and Pioneers).

Research Methodology

Both primary and secondary data sources have been utilized in the global Quantum Computing in Drug Discovery market research report. During the research process, a wide range of industry-affecting factors are examined, including:

• Governmental regulations
• Market conditions
• Competitive levels
• Historical data
• Market situation
• Technological advancements
• Upcoming developments in related businesses
• Market volatility
• Prospects, potential barriers, and challenges

• 1 Methodology and Scope

  • 1.1 Research Data

    • 1.1.1 Secondary Data

    • 1.1.2 Primary Data

    • 1.1.3 CAGR Analysis

  • 1.2 Market Size Estimation Methodology

    • 1.2.1 Bottom-Up Approach

    • 1.2.2 Top-Down Approach

  • 1.3 Market Breakdown & Data Triangulation

  • 1.4 Research Assumptions

  • 1.5 Limitations

• 2 Definition and Overview

  • 2.1 Study Objectives

  • 2.2 Market Definition

  • 2.3 Market Scope

  • 2.4 Stakeholder Analysis

  • 2.5 Currency Considered

  • 2.6 Study Period

• 3 Executive Summary

  • 3.1 Key Takeaways

  • 3.2 Top To Bottom Analysis

  • 3.3 Market Share Analysis

  • 3.4 Data Points from Key Primary Interviews

  • 3.5 Data Points from Key Secondary Databases

  • 3.6 Market Snapshot

  • 3.7 Geographical Snapshot

• 4 Dynamics

  • 4.1 Impacting Factors

    • 4.1.1 Drivers

      • 4.1.1.1 Rising Demand to Reduce Drug Discovery Time and R&D Costs Drives Market Growth
      • 4.1.1.2 Advanced Molecular Simulation Capabilities Accelerate Adoption of Quantum Computing in Drug Discovery
      • 4.1.1.3 Increasing Pharmaceutical R&D Investments Fuel Quantum Drug Discovery Market Expansion

    • 4.1.2 Restraints

      • 4.1.2.1 Limited Quantum Hardware Scalability and High Error Rates Restrain Market Growth
      • 4.1.2.2 High Implementation Costs and Infrastructure Challenges Limit Adoption

    • 4.1.3 Impact Analysis - Drivers and Restraints

    • 4.1.4 Opportunity

      • 4.1.4.1 Expansion of Quantum-as-a-Service (QaaS) Platforms Creates New Growth Avenues
      • 4.1.4.2 Growing Focus on Precision Medicine and Rare Diseases Drives Market Opportunities

    • 4.1.5 Trends

      • 4.1.5.1 Rising Strategic Collaborations Between Quantum Firms and Pharma Companies Accelerate Innovation
      • 4.1.5.2 Increasing Focus on Near-Term Use Cases Such as Molecular Simulation and Lead Optimization

    • 4.1.6 Challenges

• 5 Industry Analysis

  • 5.1 Porter’s Five Force Analysis

  • 5.2 Political Factors

  • 5.3 Social Factors

    • 5.3.1 Increasing Demand for Faster and More Efficient Drug Development

    • 5.3.2 Growing Awareness of Advanced Technologies in Healthcare Innovation

    • 5.3.3 Expansion of Collaborative Research Ecosystems

  • 5.4 Economic Factors

    • 5.4.1 Rising Investments in Quantum Computing and Pharmaceutical R&D

    • 5.4.2 Long-Term Cost Efficiency in Drug Development

    • 5.4.3 Government Funding and Policy Support for Quantum Technologies

  • 5.5 Geopolitical Factors

  • 5.6 Supply/Value Chain Analysis

  • 5.7 Pricing Analysis

  • 5.8 Regulatory Analysis

  • 5.9 Technology Landscape

  • 5.10 Innovation & R&D Trends

  • 5.11 Sustainability and ESG Analysis

  • 5.12 Risk Avoidance Model

  • 5.13 Go-To-Market (GTM) Strategy

  • 5.14 BCG Matrix

  • 5.15 Business Models Analysis

  • 5.16 Demand-Supply Gap

  • 5.17 Risk Mitigation Framework

  • 5.18 Compliance Roadmap

  • 5.19 Strategic Implications

  • 5.20 Emerging Opportunities

  • 5.21 Adoption Trends

  • 5.22 Disruption Analysis

  • 5.23 DMI Opinion

• 6 By Offering

  • 6.1 Introduction

    • 6.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering

    • 6.1.2 Market Attractiveness Index, By Offering

  • 6.2 Hardware*

    • 6.2.1 Introduction

    • 6.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 6.3 Software

  • 6.4 Services

• 7 By Quantum Technology Type

  • 7.1 Introduction

    • 7.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type

    • 7.1.2 Market Attractiveness Index, By Quantum Technology Type

  • 7.2 Superconducting Qubits*

    • 7.2.1 Introduction

    • 7.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 7.3 Trapped-Ion Qubits

  • 7.4 Photonic Qubits

  • 7.5 Quantum Annealing

  • 7.6 Topological Qubits

• 8 By Drug Discovery Workflow Stage

  • 8.1 Introduction

    • 8.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage

    • 8.1.2 Market Attractiveness Index, By Drug Discovery Workflow Stage

  • 8.2 Target Identification & Validation*

    • 8.2.1 Introduction

    • 8.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 8.3 Hit Generation/Lead Identification

  • 8.4 Lead Optimization

  • 8.5 Preclinical Candidate Selection

• 9 By Computational Application

  • 9.1 Introduction

    • 9.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application

    • 9.1.2 Market Attractiveness Index, By Computational Application

  • 9.2 Quantum Simulation*

    • 9.2.1 Introduction

    • 9.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 9.3 Quantum Optimization

  • 9.4 Quantum Machine Learning

  • 9.5 Quantum Sampling

• 10 By Deployment Model

  • 10.1 Introduction

    • 10.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model

    • 10.1.2 Market Attractiveness Index, By Deployment Model

  • 10.2 Cloud-Based*

    • 10.2.1 Introduction

    • 10.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 10.3 On-Premises

• 11 By Therapeutic Area

  • 11.1 Introduction

    • 11.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

    • 11.1.2 Market Attractiveness Index, By Therapeutic Area

  • 11.2 Oncology*

    • 11.2.1 Introduction

    • 11.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 11.3 Infectious Diseases

  • 11.4 Cardiovascular Disorders

  • 11.5 Neurological Disorders

  • 11.6 Immunological Disorders

  • 11.7 Rare & Orphan Diseases

  • 11.8 Metabolic & Endocrine Disorders

  • 11.9 Others

• 12 By End-User

  • 12.1 Introduction

    • 12.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

    • 12.1.2 Market Attractiveness Index, By End-User

  • 12.2 Pharmaceutical Companies*

    • 12.2.1 Introduction

    • 12.2.2 Market Size Analysis and Y-o-Y Growth Analysis (%)

  • 12.3 Biopharmaceutical Companies

  • 12.4 Contract Research Organizations (CROs)

  • 12.5 Academic & Research Institutes

  • 12.6 Others

• 13 By Region

  • 13.1 Introduction

    • 13.1.1 Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

    • 13.1.2 Market Attractiveness Index, By Region

  • 13.2 North America*

    • 13.2.1 Introduction

    • 13.2.2 Key Region-Specific Dynamics

    • 13.2.3 Market Size Analysis and Y-o-Y Growth Analysis (%), By Offering

    • 13.2.4 Market Size Analysis and Y-o-Y Growth Analysis (%), By Quantum Technology Type

    • 13.2.5 Market Size Analysis and Y-o-Y Growth Analysis (%), By Drug Discovery Workflow Stage

    • 13.2.6 Market Size Analysis and Y-o-Y Growth Analysis (%), By Computational Application

    • 13.2.7 Market Size Analysis and Y-o-Y Growth Analysis (%), By Deployment Model

    • 13.2.8 Market Size Analysis and Y-o-Y Growth Analysis (%), By Therapeutic Area

    • 13.2.9 Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

    • 13.2.10 Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

      • 13.2.10.1 U.S
      • 13.2.10.2 Canada
      • 13.2.10.3 Mexico

  • 13.3 Europe

    • 13.3.1 Germany

    • 13.3.2 UK

    • 13.3.3 France

    • 13.3.4 Russia

    • 13.3.5 Spain

    • 13.3.6 Italy

    • 13.3.7 Poland

    • 13.3.8 Rest of Europe

  • 13.4 Latin America

    • 13.4.1 Brazil

    • 13.4.2 Argentina

    • 13.4.3 Rest of Latin America

  • 13.5 Asia-Pacific

    • 13.5.1 China

    • 13.5.2 India

    • 13.5.3 Japan

    • 13.5.4 Australia

    • 13.5.5 South Korea

    • 13.5.6 Indonesia

    • 13.5.7 Malaysia

    • 13.5.8 Rest of Asia-Pacific

  • 13.6 Middle East and Africa

    • 13.6.1 UAE

    • 13.6.2 Saudi Arabia

    • 13.6.3 South Africa

    • 13.6.4 Israel

    • 13.6.5 Turkiye

    • 13.6.6 Rest of Middle East and Africa

• 14 Competitive Landscape

  • 14.1 Competitive Scenario

  • 14.2 Market Share Analysis - Global

  • 14.3 Market Share Analysis - North America

  • 14.4 Market Share Analysis - Europe

  • 14.5 Market Share Analysis - Asia-Pacific

  • 14.6 Mergers and Acquisitions Analysis

  • 14.7 Partner Identification Analysis

  • 14.8 Investment & Funding Landscape

  • 14.9 Strategic Alliances & Innovation Pipeline

• 15 Company Profiles

  • 15.1 IBM*

    • 15.1.1 Company Overview

    • 15.1.2 Product Portfolio and Description

    • 15.1.3 Revenue Analysis

    • 15.1.4 Pricing Analysis

    • 15.1.5 SWOT Analysis

    • 15.1.6 Recent Developments

      • 15.1.6.1 Major Deals
      • 15.1.6.2 M&A
      • 15.1.6.3 Collaboration
      • 15.1.6.4 Acquisition
      • 15.1.6.5 Joint Ventures
      • 15.1.6.6 Innovations

    • 15.1.7 Recent News

      • 15.1.7.1 Events
      • 15.1.7.2 Conferences
      • 15.1.7.3 Symposiums
      • 15.1.7.4 Webinars

  • 15.2 D-Wave Quantum Inc

  • 15.3 Microsoft

  • 15.4 Rigetti & Co, LLC

  • 15.5 Intel Corporation

  • 15.6 Fujitsu

  • 15.7 Xanadu

  • 15.8 Quantum Brilliance Pty Ltd

  • 15.9 Zapata Quantum, Inc

  • 15.10 QuEra Computing Inc

  • 15.11 Qubit Pharmaceuticals (LIST NOT EXHAUSTIVE)

• 16 Appendix

  • 16.1 About Us and Services

  • 16.2 Contact Us